TORONTO, ONTARIO -- (Marketwire) -- 02/12/13 -- BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) announced today that it has been selected to present at the first ever MicroCapClub Invitational.
The presentation can be accessed at the following link: http://microcapclub.com/2013/02/microcapclub-invitational-biosyent-rx-v/.
"At MicroCapClub we have over 170 experienced microcap investors discussing over 90 microcap companies in our members forum, and we thought as a group it would be great to showcase a few companies we believe are highly unique," said Ian Cassel, founder of MicroCapClub. "We have been following BioSyent for about a year and have been impressed with the company's profitable growth trajectory. BioSyent's strategy to in-license certain niche pharmaceutical products and distribute them in Canada has proven to be very successful. We look forward to following the company's progress in 2013 and beyond as they market and distribute additional products."
"At BioSyent we are excited about our business," said Rene Goehrum, President and CEO of BioSyent Inc. "We are pleased with our results over the last 2 1/2 years, the foundation that we have built, and our prospects for continued growth. We look forward to sharing our continuing progress with investors as 2013 unfolds."
About MicroCapClub: The MicroCapClub (mc2) is an exclusive microcap forum focused on microcap companies (sub $300m market cap). The MicroCapClub was created and founded by Ian Cassel as a way to share ideas and to learn from other seasoned like-minded microcap investors. Our goal at MicroCapClub is quality membership and quality stock ideas. If you are an experienced microcap investor, feel free to Apply Today. Go to www.microcapclub.com for additional information.
BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. The Company is focused on medications that occupy a niche in the market, that are unique either due to complexity of manufacture or provide novel technological or therapeutic advantages, or that are backed by strong partners holding intellectual property rights that are defendable. This strategy allows the Company to market these medications as brands owned by, or licensed to, it.
BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.
Rene C. Goehrum
President and CEO
Most Popular Stories
- National Retail Federation Reduces Sales Forecast
- Sporty Ford Fiesta Fires on All 3 Cylinders
- Pandora Tumbles in Late Trading
- Execs Help Entrepreneurs, Get Chevy Volts
- Small Firms Take Out the Trash in Jersey
- Citigroup Unit Paying $5 Million to Settle SEC Charges
- Amazon Hiring on Calif.'s Central Coast
- Obama Seeks Help From Central American Leaders
- 'Big Bang' Writers Hit Comic-Con
- CalPERS Still Profiting From Tainted Investments